These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 1698546)
21. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons. Taudou G; Portemer C; Jaxel C; Duguet M Biochem Pharmacol; 1993 Jan; 45(2):331-7. PubMed ID: 8382059 [TBL] [Abstract][Full Text] [Related]
24. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540 [TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211 [TBL] [Abstract][Full Text] [Related]
26. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
27. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Inaba M; Mitsuhashi J; Kawada S; Nakano H Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400 [TBL] [Abstract][Full Text] [Related]
28. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Backer LC; Allen JW; Harrington-Brock K; Campbell JA; DeMarini DM; Doerr CL; Howard DR; Kligerman AD; Moore MM Mutagenesis; 1990 Nov; 5(6):541-7. PubMed ID: 2175833 [TBL] [Abstract][Full Text] [Related]
29. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Yamashita Y; Kawada S; Fujii N; Nakano H Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001 [TBL] [Abstract][Full Text] [Related]
30. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Buckwalter CA; Lin AH; Tanizawa A; Pommier YG; Cheng YC; Kaufmann SH Cancer Res; 1996 Apr; 56(7):1674-81. PubMed ID: 8603419 [TBL] [Abstract][Full Text] [Related]
31. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
33. Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Estey E; Adlakha RC; Hittelman WN; Zwelling LA Biochemistry; 1987 Jul; 26(14):4338-44. PubMed ID: 2822085 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures. Robbie MA; Baguley BC; Denny WA; Gavin JB; Wilson WR Cancer Res; 1988 Jan; 48(2):310-9. PubMed ID: 2825971 [TBL] [Abstract][Full Text] [Related]
35. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity. Poot M; Hiller KH; Heimpel S; Hoehn H Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696 [TBL] [Abstract][Full Text] [Related]
36. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264 [TBL] [Abstract][Full Text] [Related]
37. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures. Wilson WR; Giesbrecht JL; Hill RP; Whitmore GF Cancer Res; 1981 Jul; 41(7):2809-16. PubMed ID: 6894713 [TBL] [Abstract][Full Text] [Related]
38. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin. Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Kaufmann WK; Boyer JC; Estabrooks LL; Wilson SJ Mol Cell Biol; 1991 Jul; 11(7):3711-8. PubMed ID: 1646393 [TBL] [Abstract][Full Text] [Related]
40. Amsacrine-induced lesions in DNA and their modulation by novobiocin and 2,4-dinitrophenol. Shibuya ML; Buddenbaum WE; Don AL; Utsumi H; Suciu D; Kosaka T; Elkind MM Cancer Res; 1991 Jan; 51(2):573-80. PubMed ID: 1985775 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]